IMUNON INC (IMNN) Stock Fundamental Analysis
NASDAQ:IMNN - Nasdaq - US15117N6022 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to IMNN. IMNN was compared to 571 industry peers in the Biotechnology industry. While IMNN seems to be doing ok healthwise, there are quite some concerns on its profitability. IMNN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
IMNN had negative earnings in the past year.
In the past year IMNN has reported a negative cash flow from operations.
IMNN had negative earnings in each of the past 5 years.
In the past 5 years IMNN always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -186.58%, IMNN is not doing good in the industry: 89.70% of the companies in the same industry are doing better.
IMNN has a worse Return On Equity (-483.32%) than 80.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -186.58% | ||
| ROE | -483.32% | ||
| ROIC | N/A |
ROA(3y)-66.24%
ROA(5y)-59.99%
ROE(3y)-101.8%
ROE(5y)-107.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMNN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMNN has more shares outstanding
The number of shares outstanding for IMNN has been increased compared to 5 years ago.
IMNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -62.59, we must say that IMNN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IMNN (-62.59) is worse than 95.38% of its industry peers.
IMNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -62.59 |
ROIC/WACCN/A
WACC27.63%
2.3 Liquidity
A Current Ratio of 1.51 indicates that IMNN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.51, IMNN is doing worse than 82.42% of the companies in the same industry.
IMNN has a Quick Ratio of 1.51. This is a normal value and indicates that IMNN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of IMNN (1.51) is worse than 81.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 1.51 |
3. Growth
3.1 Past
IMNN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.20%, which is quite impressive.
IMNN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)42.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
IMNN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.21% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.81%
EPS Next 2Y21.68%
EPS Next 3Y16.5%
EPS Next 5Y13.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
IMNN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMNN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IMNN's earnings are expected to grow with 16.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.68%
EPS Next 3Y16.5%
5. Dividend
5.1 Amount
IMNN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.919
+0.05 (+5.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.93%
Inst Owner Change-99.87%
Ins Owners1.14%
Ins Owner Change0%
Market Cap13.33M
Analysts82
Price Target13.46 (1364.64%)
Short Float %7.51%
Short Ratio4.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.01%
Min EPS beat(2)7.97%
Max EPS beat(2)10.04%
EPS beat(4)3
Avg EPS beat(4)9.68%
Min EPS beat(4)-24.34%
Max EPS beat(4)45.04%
EPS beat(8)4
Avg EPS beat(8)-4.7%
EPS beat(12)6
Avg EPS beat(12)-30.14%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)4.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.56 | ||
| P/tB | 3.56 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -186.58% | ||
| ROE | -483.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-66.24%
ROA(5y)-59.99%
ROE(3y)-101.8%
ROE(5y)-107.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 3739.23% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z | -62.59 |
F-Score1
WACC27.63%
ROIC/WACCN/A
Cap/Depr(3y)87.77%
Cap/Depr(5y)62.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.11%
EPS Next Y20.81%
EPS Next 2Y21.68%
EPS Next 3Y16.5%
EPS Next 5Y13.21%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.35%
OCF growth 3YN/A
OCF growth 5YN/A